Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.

Rhea-AI Summary

Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.

A fireside chat is scheduled for Thursday, June 4, 2026 at 9:20 AM ET, with a live webcast and replay available on Hemab’s investor website.

Argus May 27 session

+2.73% close to close Open Argus

Details

News Market Reaction – COAG

In the May 27 session, COAG gained 2.73%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Hemab’s participation in the 2026 Jefferies Global Healthcare Conferenc...

Analysis

This announcement highlights Hemab’s participation in the 2026 Jefferies Global Healthcare Conference, including a fireside chat on June 4, 2026 at 9:20 AM ET. It reinforces the company’s investor relations cadence following its upsized IPO and initial quarterly report earlier in May. Investors may track how the company frames its coagulation disorder pipeline, capital position, and development plans at the conference, while keeping in view prior financing milestones and early public‑market trading behavior.

Key Figures

Conference date: June 4, 2026 Presentation time: 9:20 AM ET

Conference date

June 4, 2026

Jefferies Global Healthcare Conference fireside chat

Presentation time

9:20 AM ET

Jefferies Global Healthcare Conference fireside chat

Historical Context

2 past events · Latest: May 21

2 events

1. May 21

   Q1 2026 earnings

   24h Move

   -0.6%

   Reported Q1 results with cash runway and outlined clinical and financing milestones.

2. May 04

   Upsized IPO close

   24h Move

   -1.3%

   Closed upsized IPO at $18 per share with $346.7M gross proceeds and Nasdaq listing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.

2026 Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ET
Location: New York, NY

A live webcast of the fireside chat will be available for replay under “Events & Presentations” section in the Investors section of Hemab Therapeutics’ website at hemab.com.

About Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com

Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Hemab Therapeutics (Nasdaq: COAG) present at the 2026 Jefferies Global Healthcare Conference?

Hemab Therapeutics will present a fireside chat on Thursday, June 4, 2026 at 9:20 AM ET. According to Hemab Therapeutics, the session is part of the 2026 Jefferies Global Healthcare Conference in New York, targeting investors and healthcare stakeholders.

What is the focus of Hemab Therapeutics (COAG) at the 2026 Jefferies Global Healthcare Conference?

Hemab Therapeutics will host a fireside chat and investor meetings at the 2026 Jefferies Global Healthcare Conference. According to Hemab Therapeutics, management will discuss its clinical-stage work developing therapies for blood coagulation disorders and engage directly with institutional investors.

How can investors watch Hemab Therapeutics’ 2026 Jefferies Global Healthcare Conference webcast?

Investors can watch a live webcast of Hemab Therapeutics’ fireside chat via the Investors section at hemab.com. According to Hemab Therapeutics, the replay will be available under the “Events & Presentations” section for on-demand viewing after the session.

Where is Hemab Therapeutics’ fireside chat at the 2026 Jefferies Global Healthcare Conference being held?

Hemab Therapeutics’ fireside chat will take place in New York, New York, during the 2026 Jefferies Global Healthcare Conference. According to Hemab Therapeutics, the session is scheduled for June 4, 2026 at 9:20 AM ET for conference attendees and online viewers.

What type of company is Hemab Therapeutics (Nasdaq: COAG) presenting at the 2026 Jefferies conference?

Hemab Therapeutics is a clinical-stage biotechnology company developing therapies for blood coagulation disorders. According to Hemab Therapeutics, its programs aim to reimagine treatment for these conditions, supporting life and resilience, which will be a key topic in its 2026 Jefferies conference discussions.